We conducted a mixed‐methods study of 38 male patients aged 18–39 with metastatic or locally advanced melanoma treated with first‐line PD‐1/PD‐L1/CTLA‐4 therapies at a single academic center between 2013 and 2024. The gene discussed is CTLA4; the disease is melanoma.